Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

By R. Thompson, S. Kuntz, B. Leibovich, Haidong Dong, Christine M. Lohse, W. Webster, S. Sengupta, I. Frank, A. Parker, H. Zincke and 4 more. Cancer Research, 2006

866 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/e66f3795ab4ba7149e04a03d0e45aa28c4a87d8d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Pardoll
2. Lieping Chen
3. J. Wolchok
4. W. Zou
5. S. Topalian
6. Janis Taube
7. Razelle Kurzrock
8. S. Patel

In Oncology

1. Lieping Chen
2. D. Pardoll
3. J. Wolchok
4. W. Zou
5. Razelle Kurzrock
6. S. Topalian
7. Janis Taube
8. S. Patel

Citations in the corpus

• Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010, neutral): “B7-H1 is highly upregulated in many murine and human tumors (either in tumor cells or nontransformed cells in the tumor microenvironment such as antigen-presenting cells),(12) and its expression is associated with poor outcome for patients with certain epithelial cancers.(13,14) These findings have ”
• PD-L1 Expression in Triple Negative Breast Cancer (2014, neutral): “PD-L1 is not expressed on normal epithelial tissues but is expressed on many cancers including renal cell carcinoma (20, 26), pancreatic cancer (27), ovarian cancer (28), gastric cancer (29), esophageal cancer (30), and hepatocellular carcinoma (31).”
• PD-1 and PD-1 ligands: from discovery to clinical application. (2007, neutral): “SCCHN PD-L1 ND IHC(f) (98) Lung PD-L1 No IHC(f) (104) Renal cell PD-L1 Yes IHC(f, p) (105, 106 ) Esophagus PD-L1, PD-L2 Yes (L1 and L2) RT‐PCR (107) Stomach PD-L1 Yes IHC(p) (108) Breast PD-L1 ND IHC(f) (109) Oral squamous cell PD-L1 ND IHC(f) (110) Urothelial cell PD-L1 Yes IHC(f) (111) Ovary PD-L”
• PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “Target and drug information Clinical response rate in different cancer types ienceTranslationalMedicine.org 2 Ma Phase rch 2016 Vo Cases l 8 Issue 328 References Target: PD-1 Name: Nivolumab, Opdivo, BMS-936558, MDX-1106, ONO-4538 Isotype: Humanized IgG4a Source: Bristol-Myers Squibb, Ono Pharmaceut”
• Immunostimulatory monoclonal antibodies for cancer therapy (2007, background): “In addition, the expression of B7-H1 in human malignancies correlates with a poor prognosi”
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012, result): “A 5% expression threshold was chosen to define B7-H1 positivity, in keeping with previous studies (26, 30).”
• Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (2010, background): “Third, PD-L1 is expressed at high levels in several different cancers (Latchman et al., 2001; Dong et al., 2002; Brown et al., 2003), and high expression of PD-L1 on tumors is strongly associated with poor prognosis (Thompson et al., 2006).”
• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (2015, background): “A number of PD-1/PD-L1 targeting immunotherapeutics are under clinical development across multiple histologies, though predominantly inmelanoma, RCC, andNSCLC to date (Table 2).”
• Regulatory mechanisms of PD-1/PD-L1 in cancers (2024, background): “Currently, only the function of mPD-L1 has been widely recognized and confirmed. mPD-L1 inhibits T cell function by binding to PD-1 on T cells, and its high expression is often related to tumor progression and poor prognosis in patients [142].”